Back to search
FDAFDA · Food and drugs·Recall number D-0704-2017

Mozobil (plerixafor injection) 24mg/1.2mL (20mg/mL), For Single Use Only, Rx Only, Manufactured by: Genzyme Corporation 500 Kendall Street, Cambridge, MA 02412 USA NDC: 0024-5862-01

Published May 17, 2017 · Recall initiated: September 1, 2016

Summary

FDA records drug Class III recall D-0704-2017, published May 17, 2017 and initiated September 1, 2016. Recalling firm: Sanofi-Aventis U.S. LLC; Status: Terminated; Reported quantity: 2133 vials; Lot: Lot #: 5RZ001C, 5RZ001D; Exp. 04/18. Class III means the product is not likely to cause adverse health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Labeling: Incorrect or Missing Package Insert

What to do

Voluntary: Firm initiated · Letter

Get an email if MOZOBIL has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
MOZOBIL
Manufacturer
Sanofi-Aventis U.S. LLC
Distributor
Nattionwide
Lot
Lot #: 5RZ001C, 5RZ001D; Exp. 04/18
Risk classification
Class III
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Mozobil (plerixafor injection) 24mg/1.2mL (20mg/mL), For Single Use Only, Rx Only, Manufactured by: Genzyme Corporation 500 Kendall Street, Cambridge, MA 02412 USA NDC: 0024-5862-01 recalled?

Yes. FDA published recall D-0704-2017 on May 17, 2017. Reported hazard: Labeling: Incorrect or Missing Package Insert

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: MOZOBIL.